Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs, such as several recently announced “most favored nation” (“MFN”) pricing programs.
All entries for: Intellia Therapeutics
February 26, 2026
Intellia Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
January 9, 2025
Intellia Therapeutics
Layoffs
Cambridge, MA
501-1,000 employees
Anticipated cost savings, including a net workforce reduction of approximately 27% in 2025, support company operations into 1H 2027 and through anticipated, first commercial launch in the U.S.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule